Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. II. Toxicological and general pharmacological properties.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000633:toxicity; D001241:Aspirin / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects; D001775:Blood Circulation / Q000187:drug effects; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight; D002490:Central Nervous System / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004702:Endocrine Glands / Q000187:drug effects; D005502:Food; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006827:Hydantoins / Q000494:pharmacology*; D010653:Phenylbutazone / Q000494:pharmacology; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced; D013442:Sulfinpyrazone / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology*; D014528:Uricosuric Agents / Q000494:pharmacology; D014882:Water-Electrolyte Balance; D014945:Wound Healing / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D006454:Hemoglobins; D006827:Hydantoins; D013450:Sulfones; D014528:Uricosuric Agents; D002784:Cholesterol; D010653:Phenylbutazone; D001241:Aspirin; D013442:Sulfinpyrazone